National Academies Press: OpenBook

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)

Chapter: Appendix 5: Enterotoxigenic E. coli

« Previous: Appendix 4: Cytomegalovirus
Suggested Citation:"Appendix 5: Enterotoxigenic E. coli." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

APPENDIX 5
Enterotoxigenic E. coli

DISEASE BURDEN

Epidemiology

Enterotoxigenic E. coli (ETEC) is a common causes of “traveler’s diarrhea” and a very important cause of diarrhea in infants in developing countries. ETEC can produce nausea, abdominal cramps, low fever, and a sudden-onset profuse watery diarrhea that is like a mild cause of cholera. Traveler’s diarrhea can be severe but is rarely fatal. For the purposes of the calculations in this report, the committee estimated that there are 660,000 new cases of ETEC infection each year in the United States. The incidence rate is 250 per 100,000 within all age groups and in both males and females. It is assumed that 90% of the infections occur in travelers. There are no deaths associated with ETEC infection for the purposes of the modeling in this report.

Disease Scenarios

For the purposes of the calculation in this report, the committee assumed that the vast majority of infections manifest as mild to moderate diarrhea lasting 4 days and associated with a health utility index (HUI) of .75. For 10% of the patients, the diarrhea was estimated to last 8 days.

Suggested Citation:"Appendix 5: Enterotoxigenic E. coli." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

COST INCURRED BY DISEASE

Table A5–1 summarizes the health care costs incurred by ETEC infections. For the purposes of the calculations in this report, it was assumed that all people infected with ETEC use over-the-counter medications and that only a small fraction see a physician. Costs for additional diapers and oral rehydration are included for some of the infected individuals, whether travelers or not. It is these costs which are increased for those who experience a more prolonged diarrhea.

VACCINE DEVELOPMENT

The estimates for the model are that it will take 7 years until licensure and that $240 million needs to be invested. Table 4–1 summarizes vaccine development assumptions for all vaccines considered in this report.

VACCINE PROGRAM CONSIDERATIONS

Target Population

The target population was estimated to include the annual birth cohort and overseas travelers. For the purposes of this report, the number of targeted travelers is 2,500,000 annually. It is estimated that 90% of infants and 30% of travlers will receive the immunization.

Vaccine Schedule, Efficacy, and Costs

The committee estimated that this vaccine would cost $50 per dose and that vaccine administration would cost an additional $10. The committee has accepted default assumptions for this vaccine that it will require a series of 3 doses and that efficacy will be 75%. Table 4–1 summarizes vaccine program assumptions for all vaccines considered in this report.

RESULTS

If a vaccine program for ETEC were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the QALYs gained would be 1,600. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the QALYs gained would be 280.

Suggested Citation:"Appendix 5: Enterotoxigenic E. coli." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

Table A5–1 Health Care Costs Associated with ETEC Disease

 

% of Cases

Duration (years)

% with Care

Cost per Case

Cost per Unit

Units per Case

Form of Treatment

Mile-moderate illness

90%

 

Diarrhea

 

0.0110

100%

$10

$10

1.0

Medication A

0.0110

15%

$50

$50

1.0

Physician A

0.0110

15%

$10

$10

1.0

Other costs (diapers/oral rehydration therapy)

Prolonged illness

10%

 

Acute manifestations

 

0.0219

100%

$10

$10

1.0

Medication A

0.0219

15%

$50

$50

1.0

Physician A

0.0219

15%

$20

$10

2.0

Other costs (diapers/oral rehydration therapy)

Suggested Citation:"Appendix 5: Enterotoxigenic E. coli." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

If a vaccine program for ETEC were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the health care costs saved would be $11.7 million. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the health care costs saved would be $2 million.

If a vaccine program for ETEC were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the program cost would be $1.2 billion. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the program cost would be $550 million.

Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $7.2 million for a ETEC vaccine.

If a vaccine program were implemented today and the vaccine were 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is $700,000. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is $2 million.

See Chapters 4 and 5 for details on the methods and assumptions used by the committee for the results reported.

READING LIST

Braden C, Keusch GT. Diarrhea and Dysentery-Causing Escherichia Coli. In: Textbook of Pediatric Infectious Diseases. RD Feigin and JD Cherry eds. Philadelphia, PA: WB Saunder Company, 1992, pp. 607–620.

Suggested Citation:"Appendix 5: Enterotoxigenic E. coli." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 173
Suggested Citation:"Appendix 5: Enterotoxigenic E. coli." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 174
Suggested Citation:"Appendix 5: Enterotoxigenic E. coli." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 175
Suggested Citation:"Appendix 5: Enterotoxigenic E. coli." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 176
Next: Appendix 6: Epstein-Barr Virus »
Vaccines for the 21st Century: A Tool for Decisionmaking Get This Book
×
Buy Hardback | $72.95 Buy Ebook | $59.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Vaccines have made it possible to eradicate the scourge of smallpox, promise the same for polio, and have profoundly reduced the threat posed by other diseases such as whooping cough, measles, and meningitis.

What is next? There are many pathogens, autoimmune diseases, and cancers that may be promising targets for vaccine research and development.

This volume provides an analytic framework and quantitative model for evaluating disease conditions that can be applied by those setting priorities for vaccine development over the coming decades. The committee describes an approach for comparing potential new vaccines based on their impact on morbidity and mortality and on the costs of both health care and vaccine development. The book examines:

  • Lessons to be learned from the polio experience.
  • Scientific advances that set the stage for new vaccines.
  • Factors that affect how vaccines are used in the population.
  • Value judgments and ethical questions raised by comparison of health needs and benefits.

The committee provides a way to compare different forms of illness and set vaccine priorities without assigning a monetary value to lives. Their recommendations will be important to anyone involved in science policy and public health planning: policymakers, regulators, health care providers, vaccine manufacturers, and researchers.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!